The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / TNF Inhibitors & Pregnancy: How Well Does the Treatment Guidance Work?

TNF Inhibitors & Pregnancy: How Well Does the Treatment Guidance Work?

October 21, 2021 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF
ajt/shutterstock.com

ajt/shutterstock.com

Ghalandari et al. analyzed cord blood levels of tumor necrosis factor inhibitors (TNFi’s) in post-partum women with rheumatic disease, seeking to validate the guidance outlined in EULAR’s document on points to consider for the use of anti-rheumatic drugs before and during pregnancy and lactation. Published in 2016, the document recommends the discontinuation of treatment with adalimumab and infliximab at week 20 of pregnancy and the discontinuation of etanercept at 30–32 weeks. Certolizumab pegol can be continued throughout pregnancy, up to 38 weeks.1,2

You Might Also Like
  • Prenatal TNF Inhibitor Exposure Not Linked to Serious Infections
  • TNF Blocking Drugs Persist in Infants after Exposure In-Utero
  • RA Patients May Be Less Likely to Discontinue Etanercept Than Other TNF Inhibitors
Explore This Issue
November 2021
Also By This Author
  • Baricitinib May Exhibit Better Efficacy Than Adalimumab for RA

For the study, the researchers used patient data from an ongoing, prospective cohort study on inflammatory rheumatic diseases and pregnancy at the Erasmus Medical Center, Rotterdam, the Netherlands (Preconceptional Counselling in Active Rheumatoid Arthritis [PreCARA]; NCT01345071).3 Patients whose cord blood was collected at birth were included in their analysis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The patients: Patients in the PreCARA cohort received a modified treat-to-target approach for rheumatoid arthritis (48%), spondyloarthropathies (23%), psoriatic arthritis (20%), juvenile idiopathic arthritis (5%) and other rheumatic diseases (4%).4 They had a mean age of 31.2±3.9 years, a disease duration of 8.0±6.5 years at study inclusion and disease activity scores (DAS28-CRP) of 2.2±0.8 in the third trimester. Additionally, 44% (n=49) of the patients had never before given birth to a live baby.

Patients became pregnant while taking a TNFi (e.g., adalimumab, etanercept or infliximab) and then discontinued it at the advised gestational age from the EULAR guidance. After discontinuing the TNFi, these women switched to certolizumab pegol and/or prednisone. Certolizumab pegol was discontinued at the gestational age of 38 weeks to prevent maternal infections during delivery. This recommendation in the EULAR document was based on expert opinion.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In each trimester, maternal blood was collected at times unrelated to TNFi administration and analyzed for the concentration of TNFi. Cord blood was collected at birth and also analyzed for the concentration of TNFi in it.

The Results

Ghalandari et al. analyzed the samples of 111 patients from the PreCARA cohort. Most patients stopped TNFi treatment prior to the EULAR-recommended gestational age. Adalimumab (n=25) was stopped before 20 weeks of pregnancy by 20 patients (80%), etanercept (n=30) was stopped before 30 weeks of pregnancy by 29 patients (97%), and infliximab (n=14) was stopped before 20 weeks of pregnancy by 10 patients (71%). The median gestational age when adalimumab was stopped was 19 weeks, the median gestational age when etanercept was stopped was 25 weeks, and the median gestational age when infliximab was stopped was 18.4 weeks. For certolizumab pegol (n=68), the median gestational age when treatment was stopped was 37 weeks (interquartile range [IQR]: 34.1–38.1 weeks), and the median time between the last dose of certolizumab pegol and delivery was 15 days (IQR: 2–34 days).

Pages: 1 2 3 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: EULAR, pregnancy, pregnant women, TNF inhibitors, TNFi, WomenIssue: November 2021

You Might Also Like:
  • Prenatal TNF Inhibitor Exposure Not Linked to Serious Infections
  • TNF Blocking Drugs Persist in Infants after Exposure In-Utero
  • RA Patients May Be Less Likely to Discontinue Etanercept Than Other TNF Inhibitors
  • Certolizumab Pegol Usage Compatible with Breastfeeding

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)